Under terms of the agreement, NorthStar will provide Clarity Pharmaceuticals with Cu-67, a beta-emitting radioisotope with potential applications as a targeted radiopharmaceutical for treatment of a range of cancers.
NorthStar will be a major US supplier of Cu-67 for Clarity.
Copper-67 (Cu-67) is a short-range, beta-emitting radioisotope which is attractive for medical purposes due to its ability to carry sufficient radiation energy to cause cell death in targeted cells while having a sufficiently short half-life to limit unwanted radioactivity in patients.
Cu-67 is being investigated for therapeutic purposes across a wide range of adult and childhood cancers.
Potential radiotherapeutic targets include prostate cancer, breast cancer, neuroendocrine tumors, neuroblastoma, glioma, lymphoma, ovarian and bladder cancers.
In order to develop safe and effective targeted therapies, a chelator, which strongly binds Cu-67 to the targeting agent, is required.
Clarity Pharmaceuticals has successfully developed a highly specific and highly stable chelator for copper isotopes and is now progressing a range of radiopharmaceuticals based on its proprietary MeCOSar chelator.
NorthStar is developing a proprietary process for commercial-scale production of Cu-67 to meet demand for clinical research and treatment.
NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging and therapeutic purposes.
Founded in 2006 and based in Beloit, Wis., NorthStar Medical Technologies is the parent organisation of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC.
NorthStar Medical Radioisotopes is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research.
Clarity is a personalised medicine company focused on the treatment of serious diseases.
The company is in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients